Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000591044 | SCV000706683 | uncertain significance | not provided | 2017-02-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001456835 | SCV001660624 | likely benign | Wolman disease | 2024-04-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003278933 | SCV004005718 | likely benign | Cardiovascular phenotype | 2023-04-14 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
GENin |
RCV004820062 | SCV005441696 | likely benign | Lysosomal acid lipase deficiency | 2023-06-12 | criteria provided, single submitter | clinical testing | This is a synonymous (silent) variant that is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved. Therefore this variant has been classified as Likely Benign (BP4, BP7). |
Prevention |
RCV004543370 | SCV004758625 | likely benign | LIPA-related disorder | 2021-09-16 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |